Abstract 759: Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood

Recent studies indicate that sunitinib, a tyrosine kinase inhibitor, could decease accumulation of myeloid-derived suppressor cells (MDSC) in tumors and also in peripheral blood. This study aims to investigate the behavior and dynamic profile of myeloid-derived suppressor cells in tumor tissues and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2016-07, Vol.76 (14_Supplement), p.759-759
Hauptverfasser: Chen, Fang-Hsin, Fu, Sheng-Yung, Wang, Chun-Chieh, Chiang, Chi-Shiun, Hong, Ji-Hong
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 759
container_issue 14_Supplement
container_start_page 759
container_title Cancer research (Chicago, Ill.)
container_volume 76
creator Chen, Fang-Hsin
Fu, Sheng-Yung
Wang, Chun-Chieh
Chiang, Chi-Shiun
Hong, Ji-Hong
description Recent studies indicate that sunitinib, a tyrosine kinase inhibitor, could decease accumulation of myeloid-derived suppressor cells (MDSC) in tumors and also in peripheral blood. This study aims to investigate the behavior and dynamic profile of myeloid-derived suppressor cells in tumor tissues and peripheral blood of sunitinib-treated mice bearing prostate adenocarcinoma TRAMP-C1 tumors. To this end, 3×106 TRAMP-C1 tumor cells were inoculated at shank muscle of C57BL6/J mouse and sunitinib was administered by intraperitoneal injection of a daily dose of 20mg/kg into mice bearing 4 mm diameter tumor. Comparing to tumors in untreated group, sunitinib administration slightly delayed tumor growth delay for 2 days, but significantly decreased micro-vascular density and induced chronic hypoxia in tumors, resulting in the specific accumulation of CD11b+Gr-1+ MDSCs at the tumor necrotic region within CA-IX positive chronic hypoxic area. Flow cytometry was used to analyze the change of CD11b+ myeloid cells within tumor tissues and peripheral blood. Results showed that sunitinib treatment decreased the percentage of CD11b+Ly6G-LyC- tumor-associated macrophages (TAMs), but increased the percentage of CD11b+Ly6G-Ly6C+ monocytic MDSCs (M-MDSCs) while had no effect on CD11b+Ly6G+Ly6C+ neutrophilic MDSCs (N-MDSCs) within tumor tissues. In contrast, both the percentage of N-MDSCs and M-MDSC were expanded in peripheral blood of sunitinib-treated mice. Multiplex immunoassay showed significant increase of CCL2, CCL3, CCL5, CXCL5, IL-17a, GM-CSF, G-CSF and VEGF-A in tumor tissues, but only CXCL5, IL-á, IL-6 and G-CSF in the peripheral blood of sunitinib-treated mice were affected. In conclusion, this study shows that sunitinib has anti-vascular effect and could disrupt the recruitment of CD11b+Ly6G-Ly6C- TAMs into tumors. We also propose that sunitinib might exert different effects on tumor microenvironment and peripheral blood. Citation Format: Fang-Hsin Chen, Sheng-Yung Fu, Chun-Chieh Wang, Chi-Shiun Chiang, Ji-Hong Hong. Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 759.
doi_str_mv 10.1158/1538-7445.AM2016-759
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1846403777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1846403777</sourcerecordid><originalsourceid>FETCH-LOGICAL-c787-dcfcfebc4bb1fd77a34b91d046921de00e38dad82a4470fca95269097641c1a73</originalsourceid><addsrcrecordid>eNo9kE1LxDAQhoMouH78Aw85eumatGnTelsWv2DFg3sPaTJ1I9kmZlph_fW2rHga5uV5h-Eh5IazJedlfcfLos6kEOVy9ZozXmWybE7I4j8-JQvGWJ2VQubn5ALxc1pLzsoF-Vm1OCRtBjp17un72LvB9a6lO400xBjQDUBT8IB0CDTBx-j1lAw7oPsD-OBsZiG5b7AUxxgTIIZEDXiP1PV0GPchIdW9pXHC4g6S9rT1IdgrctZpj3D9Ny_J9vFhu37ONm9PL-vVJjOylpk1nemgNaJteWel1IVoG26ZqJqcW2AMitpqW-daCMk6o5syrxrWyEpww7UsLsnt8WxM4WsEHNTe4fyf7iGMqHgtKsEKKWdUHFGTAmKCTsXk9jodFGdqNq1mpWpWqo6m1WSt-AWd13Oz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1846403777</pqid></control><display><type>article</type><title>Abstract 759: Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood</title><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Chen, Fang-Hsin ; Fu, Sheng-Yung ; Wang, Chun-Chieh ; Chiang, Chi-Shiun ; Hong, Ji-Hong</creator><creatorcontrib>Chen, Fang-Hsin ; Fu, Sheng-Yung ; Wang, Chun-Chieh ; Chiang, Chi-Shiun ; Hong, Ji-Hong</creatorcontrib><description>Recent studies indicate that sunitinib, a tyrosine kinase inhibitor, could decease accumulation of myeloid-derived suppressor cells (MDSC) in tumors and also in peripheral blood. This study aims to investigate the behavior and dynamic profile of myeloid-derived suppressor cells in tumor tissues and peripheral blood of sunitinib-treated mice bearing prostate adenocarcinoma TRAMP-C1 tumors. To this end, 3×106 TRAMP-C1 tumor cells were inoculated at shank muscle of C57BL6/J mouse and sunitinib was administered by intraperitoneal injection of a daily dose of 20mg/kg into mice bearing 4 mm diameter tumor. Comparing to tumors in untreated group, sunitinib administration slightly delayed tumor growth delay for 2 days, but significantly decreased micro-vascular density and induced chronic hypoxia in tumors, resulting in the specific accumulation of CD11b+Gr-1+ MDSCs at the tumor necrotic region within CA-IX positive chronic hypoxic area. Flow cytometry was used to analyze the change of CD11b+ myeloid cells within tumor tissues and peripheral blood. Results showed that sunitinib treatment decreased the percentage of CD11b+Ly6G-LyC- tumor-associated macrophages (TAMs), but increased the percentage of CD11b+Ly6G-Ly6C+ monocytic MDSCs (M-MDSCs) while had no effect on CD11b+Ly6G+Ly6C+ neutrophilic MDSCs (N-MDSCs) within tumor tissues. In contrast, both the percentage of N-MDSCs and M-MDSC were expanded in peripheral blood of sunitinib-treated mice. Multiplex immunoassay showed significant increase of CCL2, CCL3, CCL5, CXCL5, IL-17a, GM-CSF, G-CSF and VEGF-A in tumor tissues, but only CXCL5, IL-á, IL-6 and G-CSF in the peripheral blood of sunitinib-treated mice were affected. In conclusion, this study shows that sunitinib has anti-vascular effect and could disrupt the recruitment of CD11b+Ly6G-Ly6C- TAMs into tumors. We also propose that sunitinib might exert different effects on tumor microenvironment and peripheral blood. Citation Format: Fang-Hsin Chen, Sheng-Yung Fu, Chun-Chieh Wang, Chi-Shiun Chiang, Ji-Hong Hong. Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 759.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/1538-7445.AM2016-759</identifier><language>eng</language><ispartof>Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.759-759</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids></links><search><creatorcontrib>Chen, Fang-Hsin</creatorcontrib><creatorcontrib>Fu, Sheng-Yung</creatorcontrib><creatorcontrib>Wang, Chun-Chieh</creatorcontrib><creatorcontrib>Chiang, Chi-Shiun</creatorcontrib><creatorcontrib>Hong, Ji-Hong</creatorcontrib><title>Abstract 759: Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood</title><title>Cancer research (Chicago, Ill.)</title><description>Recent studies indicate that sunitinib, a tyrosine kinase inhibitor, could decease accumulation of myeloid-derived suppressor cells (MDSC) in tumors and also in peripheral blood. This study aims to investigate the behavior and dynamic profile of myeloid-derived suppressor cells in tumor tissues and peripheral blood of sunitinib-treated mice bearing prostate adenocarcinoma TRAMP-C1 tumors. To this end, 3×106 TRAMP-C1 tumor cells were inoculated at shank muscle of C57BL6/J mouse and sunitinib was administered by intraperitoneal injection of a daily dose of 20mg/kg into mice bearing 4 mm diameter tumor. Comparing to tumors in untreated group, sunitinib administration slightly delayed tumor growth delay for 2 days, but significantly decreased micro-vascular density and induced chronic hypoxia in tumors, resulting in the specific accumulation of CD11b+Gr-1+ MDSCs at the tumor necrotic region within CA-IX positive chronic hypoxic area. Flow cytometry was used to analyze the change of CD11b+ myeloid cells within tumor tissues and peripheral blood. Results showed that sunitinib treatment decreased the percentage of CD11b+Ly6G-LyC- tumor-associated macrophages (TAMs), but increased the percentage of CD11b+Ly6G-Ly6C+ monocytic MDSCs (M-MDSCs) while had no effect on CD11b+Ly6G+Ly6C+ neutrophilic MDSCs (N-MDSCs) within tumor tissues. In contrast, both the percentage of N-MDSCs and M-MDSC were expanded in peripheral blood of sunitinib-treated mice. Multiplex immunoassay showed significant increase of CCL2, CCL3, CCL5, CXCL5, IL-17a, GM-CSF, G-CSF and VEGF-A in tumor tissues, but only CXCL5, IL-á, IL-6 and G-CSF in the peripheral blood of sunitinib-treated mice were affected. In conclusion, this study shows that sunitinib has anti-vascular effect and could disrupt the recruitment of CD11b+Ly6G-Ly6C- TAMs into tumors. We also propose that sunitinib might exert different effects on tumor microenvironment and peripheral blood. Citation Format: Fang-Hsin Chen, Sheng-Yung Fu, Chun-Chieh Wang, Chi-Shiun Chiang, Ji-Hong Hong. Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 759.</description><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo9kE1LxDAQhoMouH78Aw85eumatGnTelsWv2DFg3sPaTJ1I9kmZlph_fW2rHga5uV5h-Eh5IazJedlfcfLos6kEOVy9ZozXmWybE7I4j8-JQvGWJ2VQubn5ALxc1pLzsoF-Vm1OCRtBjp17un72LvB9a6lO400xBjQDUBT8IB0CDTBx-j1lAw7oPsD-OBsZiG5b7AUxxgTIIZEDXiP1PV0GPchIdW9pXHC4g6S9rT1IdgrctZpj3D9Ny_J9vFhu37ONm9PL-vVJjOylpk1nemgNaJteWel1IVoG26ZqJqcW2AMitpqW-daCMk6o5syrxrWyEpww7UsLsnt8WxM4WsEHNTe4fyf7iGMqHgtKsEKKWdUHFGTAmKCTsXk9jodFGdqNq1mpWpWqo6m1WSt-AWd13Oz</recordid><startdate>20160715</startdate><enddate>20160715</enddate><creator>Chen, Fang-Hsin</creator><creator>Fu, Sheng-Yung</creator><creator>Wang, Chun-Chieh</creator><creator>Chiang, Chi-Shiun</creator><creator>Hong, Ji-Hong</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20160715</creationdate><title>Abstract 759: Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood</title><author>Chen, Fang-Hsin ; Fu, Sheng-Yung ; Wang, Chun-Chieh ; Chiang, Chi-Shiun ; Hong, Ji-Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c787-dcfcfebc4bb1fd77a34b91d046921de00e38dad82a4470fca95269097641c1a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Fang-Hsin</creatorcontrib><creatorcontrib>Fu, Sheng-Yung</creatorcontrib><creatorcontrib>Wang, Chun-Chieh</creatorcontrib><creatorcontrib>Chiang, Chi-Shiun</creatorcontrib><creatorcontrib>Hong, Ji-Hong</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Fang-Hsin</au><au>Fu, Sheng-Yung</au><au>Wang, Chun-Chieh</au><au>Chiang, Chi-Shiun</au><au>Hong, Ji-Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract 759: Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><date>2016-07-15</date><risdate>2016</risdate><volume>76</volume><issue>14_Supplement</issue><spage>759</spage><epage>759</epage><pages>759-759</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><abstract>Recent studies indicate that sunitinib, a tyrosine kinase inhibitor, could decease accumulation of myeloid-derived suppressor cells (MDSC) in tumors and also in peripheral blood. This study aims to investigate the behavior and dynamic profile of myeloid-derived suppressor cells in tumor tissues and peripheral blood of sunitinib-treated mice bearing prostate adenocarcinoma TRAMP-C1 tumors. To this end, 3×106 TRAMP-C1 tumor cells were inoculated at shank muscle of C57BL6/J mouse and sunitinib was administered by intraperitoneal injection of a daily dose of 20mg/kg into mice bearing 4 mm diameter tumor. Comparing to tumors in untreated group, sunitinib administration slightly delayed tumor growth delay for 2 days, but significantly decreased micro-vascular density and induced chronic hypoxia in tumors, resulting in the specific accumulation of CD11b+Gr-1+ MDSCs at the tumor necrotic region within CA-IX positive chronic hypoxic area. Flow cytometry was used to analyze the change of CD11b+ myeloid cells within tumor tissues and peripheral blood. Results showed that sunitinib treatment decreased the percentage of CD11b+Ly6G-LyC- tumor-associated macrophages (TAMs), but increased the percentage of CD11b+Ly6G-Ly6C+ monocytic MDSCs (M-MDSCs) while had no effect on CD11b+Ly6G+Ly6C+ neutrophilic MDSCs (N-MDSCs) within tumor tissues. In contrast, both the percentage of N-MDSCs and M-MDSC were expanded in peripheral blood of sunitinib-treated mice. Multiplex immunoassay showed significant increase of CCL2, CCL3, CCL5, CXCL5, IL-17a, GM-CSF, G-CSF and VEGF-A in tumor tissues, but only CXCL5, IL-á, IL-6 and G-CSF in the peripheral blood of sunitinib-treated mice were affected. In conclusion, this study shows that sunitinib has anti-vascular effect and could disrupt the recruitment of CD11b+Ly6G-Ly6C- TAMs into tumors. We also propose that sunitinib might exert different effects on tumor microenvironment and peripheral blood. Citation Format: Fang-Hsin Chen, Sheng-Yung Fu, Chun-Chieh Wang, Chi-Shiun Chiang, Ji-Hong Hong. Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 759.</abstract><doi>10.1158/1538-7445.AM2016-759</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.759-759
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_1846403777
source American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
title Abstract 759: Sunitinib has opposite roles to regulate the myeloid-derived suppressor cells in tumors and peripheral blood
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T21%3A39%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%20759:%20Sunitinib%20has%20opposite%20roles%20to%20regulate%20the%20myeloid-derived%20suppressor%20cells%20in%20tumors%20and%20peripheral%20blood&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Chen,%20Fang-Hsin&rft.date=2016-07-15&rft.volume=76&rft.issue=14_Supplement&rft.spage=759&rft.epage=759&rft.pages=759-759&rft.issn=0008-5472&rft.eissn=1538-7445&rft_id=info:doi/10.1158/1538-7445.AM2016-759&rft_dat=%3Cproquest_cross%3E1846403777%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1846403777&rft_id=info:pmid/&rfr_iscdi=true